secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2025-06-25T23:59:59+00:00
Accession:  0001193125-25-146135
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sanofi to advance Kymera's KT-485 IRAK4 degrader; $20M milestone achieved
-------------------------------------------------------------------------

- Sanofi selects KT-485 for Phase 1 testing in immuno-inflammatory diseases, expected to start next year; KT-474 will not advance.
- KT-485 showed improved potency, selectivity, and safety profile vs KT-474 in preclinical testing.
- Kymera earned a $20M milestone in Q2 2025 for preclinical activities on KT-485.
- Kymera eligible for up to $975M in milestones plus double-digit royalties; may opt-in to 50/50 U.S. profit share.
- Sanofi exercised participation election right for IRAK4 target under collaboration agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000119312525146135/0001193125-25-146135-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000119312525146135/d89458d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-146135

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer